Physician profile
Walter Tanner
NPI 1063011005
$479.45
in general payments reported to CMS, 2019-2025
13 companies · $89.29 in 2025
The $89.29 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.54 · 2022: $129 · 2023: $178 · 2024: $42.03 · 2025: $89.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $133.95 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $87.22 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $44.93 | 2022-2023 | |
| Sanofi Pasteur INC. | $37.79 | 2024-2025 | |
| Amgen INC. | $30.89 | 2021-2023 | Repatha, Otezla |
| Astellas Pharma US INC | $28.33 | 2021-2023 | Veozah |
| Merck Sharp & Dohme LLC | $21.94 | 2025 | Enflonsia, Vaxneuvance, Gardasil 9 |
| Ossur Americas, INC. | $18.67 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.68 | 2022 | |
| Dexcom, INC. | $15.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.70 | 2024 | Flumist Quadrivalent |
| Aytu Biopharma, INC. | $14.15 | 2024 | Karbinal |
| Paratek Pharmaceuticals, INC. | $13.34 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.